<DOC>
	<DOC>NCT00436592</DOC>
	<brief_summary>The purpose of this study is to assess the safety and feasibility of the NeuroFloâ„¢ catheter in treating patients with ischemic stroke whose last time symptom-free was between 8-24 hours prior to treatment. The NeuroFlo device is intended to increase blood flow to the brain and potentially reduce the damage caused by stroke.</brief_summary>
	<brief_title>Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients</brief_title>
	<detailed_description>The study is a prospective, single arm treatment feasibility trial to determine the baseline safety and feasibility of the NeuroFlo device in acute ischemic stroke patients whose last known time symptom-free is between 8-24 hours. A maximum of 25 patients at 5 US sites and 25 patients at 10 Canadian &amp; European sites may be enrolled in this initial study phase. An independent data safety and monitoring board will assess the safety of the treatment on a routine basis.</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Ischemic stroke NIHSS between 420 Time from symptom onset between 8 and 24 hours Hemorrhagic stroke Certain types of heart disease Kidney disease Other conditions the doctor will assess</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>acute</keyword>
	<keyword>ischemic</keyword>
	<keyword>stroke</keyword>
	<keyword>device</keyword>
	<keyword>treatment</keyword>
</DOC>